Newsroom



News

PHCentral News is gathered daily to bring you the latest developments in pulmonary hypertension treatments and research as well as stories we think are useful on an array of topics.  Under current news, you will find a dynamic list of stories for the last thirty (30) days.  You will find older news stories in our archives.    Stories about specific treatments can also be found in the medical section.

If you run across a PH news story we've missed or important story with broad appeal, please send us the link and we'll make sure it gets added.   Send news:  contact/info+phcentral+org.



  • October 24, 2014
  • New PAH Research Highlights Effect of Disease on Muscles, Importance of Exercise
  • (Pulmonary Hypertension News) Exercise and fitness are two health factors that invariably affect prognoses for most chronic, progressive diseases. Given the stress and immobility that come as a result of illness, maintaining fitness to the best of the patient’s ability is generally a best practice for maximizing quality of life and lifespan. However, new PAH research suggests that patients’ muscles are affected by the disease at the cellular level, and that any measure of exercise can have a palpably positive impact on health and well being.
  •   
  • Plant grown treatment for pulmonary hypertension
  • (Digital Journal) A new medication has been developed, which could retail at a far lower cost. The new product targets angiotensin II suppression hormones (angiotensins are peptide hormones that causes vasoconstriction and a subsequent increase in blood pressure.) The medication was formulated inside plant leaves. The material is then extracted, freeze-dried and then encased in capsules.

    In studies, Pharmaceutical International reports, the drug has been administered to rats. These studies found that the pulmonary hypertension levels in the rats dropped by around 20 percent. After two weeks of administration, the pressure levels inside the rats decreased by a further 12 percent. The rat based-trials not only produced pulmonary hypertension pressure drops of more than 30 percent, the drug further helped to improve heart function. The studies were conducted by the American Heart Association and the National Heart, Lung and Blood Institute.
  •   
  • October 23, 2014
  • Actelion intends to file for selexipag's approval for PAH in the U.S. and the EU soon
  • (Zacks.com) "Actelion intends to file for selexipag’s approval for the treatment of pulmonary arterial hypertension in the U.S. and the EU in the coming months. The company will also present data from the GRIPHON study on selexipag in the next few months."
    According to Actelion's 3Q Earnings-Report..
  •   
  • October 22, 2014
  • Pluristem Advances its Second Major Cell Therapy Product Line from Development to Large-Scale Manufacturing
  • (Pluristem) HAIFA, ISRAEL, October 21, 2014--Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PLTR), a leading developer of placenta-based cell therapy products, announced today that it has completed development of its second major product line, and can now begin manufacturing the cells on a large-scale at its state-of-the art facility in order to meet demand for anticipated studies in a range of hematologic conditions. This second cell product candidate, called PLX-RAD, was created using Pluristem’s proprietary three dimensional cellexpansion technology platform. The Company’s first product, PLX-PAD, is already in clinical trials for the treatment of peripheral artery disease, muscle injury and pulmonary arterial hypertension...
  •   
  • October 21, 2014
  • PH Patient Hemodynamics Unaffected By Noninvasive Ventilation
  • (Pulmonary Hypertension News) A recent study conducted in Brazil suggests noninvasive positive pressure ventilation (CPAP) does not contribute to ventilation-related complications in pulmonary hypertension patients. These results are encouraging, as there had been previous reports demonstrating that mechanical ventilation of patients with pulmonary hypertension results in unfavorable hemodynamic effects.
    Until this study,”Hemodynamic Effects of Noninvasive Ventilation in Patients with Venocapillary Pulmonary Hypertension,” published in SciELO, was conducted, little was known about the hemodynamic effects of CPAP on patients with pulmonary hypertension without left ventricular dysfunction. The team studied 38 pulmonary hypertension patients..
  •   
  • FDA Approves Ofev and Esbriet for Idiopathic Pulmonary Fibrosis
  • (Medscape) The US Food and Drug Administration (FDA) has approved for marketing nintedanib (Ofev, Boehringer Ingelheim) and pirfenidone (Esbriet, InterMune) for patients with idiopathic pulmonary fibrosis (IPF).

    Individuals with IPF have progressively scarred lungs over time and experience shortness of breath, cough, and difficulty participating in normal daily activities.

    Prior to these approvals, treatments for IPF included oxygen therapy, pulmonary rehabilitation, and lung transplantation.

    Nintedanib  and pirfenidone  were granted approval through a triple-path process: fast track, orphan product, and breakthrough designations. The approvals today come ahead of pirfenidone's and nintedanib's expected approval dates of November 23, 2014, and January 2, 2015, respectively...


  •   
  • October 20, 2014
  • Pulmonary arterial hypertension-related myopathy: An overview of current data and future perspectives
  • (Nutrition, Metabolism and Cardiovascular Diseases --) Skeletal muscle impairment is a key determinant of exercise intolerance in PAH.
    Several cellular abnormalities are present in skeletal muscle of PAH patients.
    These abnormalities finally culminate in muscle atrophy and reduced contractility.
    Exercise training improves muscle function and clinical outcomes..

  •   
  • October 19, 2014
  • Pulmonary Hypertension & Pulmonary Arterial Hypertension: Categories, Risk Factors And Treatments Profiled
  • (Pulmonary Hypertension News) Pulmonary Hypertension (PH) and Pulmonary Arterial Hypertension (PAH) are not popular topics of media coverage and popular conversation in the way that Cancer and Heart Disease are. Despite increasing numbers of people diagnosed with PH/PAH worldwide, pulmonary hypertension has been a historically neglected disease. Which is a bit puzzling, since PH/PAH symptoms can be debilitating, initially including shortness of breath and fatigue, but if left untreated, they can lead to right ventricular failure, volume overload, and death. PAH has a high mortality rate, with 60 to 80 percent of patients dying within five years of diagnosis. However, because the molecular processes associated with the disease are difficult to define simply, understanding PH therefore remains enigmatic to most laypeople.
  •   
  • A Crossover Randomised Controlled Trial of Oral Mandibular Advancement Devices for Obstructive Sleep Apnoea-Hypopnoea (TOMADO)
  • (Medscape) Mandibular advancement devices (MADs) are used to treat obstructive sleep apnoea-hypopnoea syndrome (OSAHS) but evidence is lacking regarding their clinical and cost-effectiveness in less severe disease.
  •   
  • October 18, 2014
  • Pulmonary Arterial Hypertension: A Better Understanding of the Three New Drug Therapies
  • (Medscape) Pulmonary arterial hypertension (PAH) is historically an incurable disease with a poor prognosis. However, recent advances in treating PAH have increased arsenal of treatments available to the physician for managing its symptoms.
  •   
  • New Insights Into Hypoxia-induced Pulmonary Hypertension Reveal Key Signaling Pathways
  • (Pulmonary Hypertension News) A new study entitled “mTORC1 Is Involved in Hypoxia-Induced Pulmonary Hypertension Through the Activation of Notch3” published in Journal of Cellular Physiology reports that both mTORC1 and Notch3 signaling pathways are associated with Hypoxia-Induced Pulmonary Hypertension.
  •   
  • October 17, 2014
  • Vascular receptor autoantibodies implicated in SSc-PAH
  • (http://www.medwirenews.com/48/105950/General_respiratory/Vascular_receptor_autoantibodies_implicated_in_SSc-PAH.html) Autoantibodies to endothelin receptor type A (ETAR) and angiotensin receptor type-1 (AT1R) predict the development of, and mortality from, systemic sclerosis (SSc)-associated pulmonary arterial hypertension (PAH), research suggests.
  •   
  • Researchers Determine eRAP As Viable PAH Prognosticator
  • (Pulmonary Hypertension News)  new study on pulmonary arterial hypertension (PAH) entitled “Echocardiographic Assessment of Estimated Right Atrial Pressure and Size Predicts Mortality in Pulmonary Arterial Hypertension” was published in Chest by Dr. Christopher Austin, part of Dr. Brian Shapiro’s group from Division of Cardiovascular Disease at the Mayo Clinic, showing that estimated right atrial pressure (eRAP), measured by echocardiography, may be an effective prognostic indicator in patients with pulmonary arterial hypertension (PAH).
  •   
  • HRQoL goals may improve outcome in PAH
  • (MedWire News) Health-related quality of life (HRQoL) before and during treatment for pulmonary arterial hypertension (PAH) is significantly associated with survival, Brazilian researchers report.
  •   
  • PAH Combination Therapy Lowers Hospitalization Rate & Worsening PAH in New study
  • (Pulmonary Hypertension News) The results from the randomized controlled AMBITION study to determine the efficacy of treating patients with Pulmonary Arterial Hypertension (PAH) with a combination of ambrisentan/tadalafil, when compared to ambrisenan or taladafil as monotherapies, were presented at this year’s European Respiratory Society (ERS) International Congress.
  •   
  • October 16, 2014
  • Swedish-Built Machine Makes Lung Transplants More Available
  • (Health Canal) The final hope for many patients with severe lung disease is a transplant – but there is a chronic shortage of donated lungs. Scientists at the University of Gothenburg and Sahlgrenska University Hospital have tested a new method that makes it possible to use lungs that previously were discarded. Twenty-two additional lung patients have already received transplants using the new method.
  •   
  • October 15, 2014
  • Sarcoidosis-associated pulmonary hypertension and lung transplantation for sarcoidosis
  • (National Library of Medicine) Abstract

    Pulmonary hypertension (PH) is a significant complication of sarcoidosis, occurring in approximately 6 to > 20% of cases, and markedly increases mortality among these patients. The clinician should exercise a high index of suspicion for sarcoidosis-associated PH (SAPH) given the nonspecific symptomatology and the limitations of echocardiography in this patient population. The pathophysiology of PH in sarcoidosis is complex and multifactorial. Importantly, there are inherent differences in the pathogenesis of SAPH compared with idiopathic pulmonary arterial hypertension, making the optimal management of SAPH controversial. In this article, we review the epidemiology, diagnosis, prognosis, and treatment considerations for SAPH. Lung transplantation (LT) is a viable therapeutic option for sarcoid patients with severe pulmonary fibrocystic sarcoidosis or SAPH refractory to medical therapy. We discuss the role for LT in patients with sarcoidosis, review the global experience with LT in this population, and discuss indications and contraindications to LT.
  •   
  • October 14, 2014
  • Emergy Department Diagnosis of PH
  • (International Journal of Emergency Medicine) A Case Report
  •   
  •  Quebec is First Canadian Province to Publicly Fund Novel Oral PAH Treatment
  • (Pulmonary Hypertension News) Quebec residents living with pulmonary arterial hypertension (PAH) now have access to a breakthrough, publicly funded drug called Opsumit (macitentan), a once-a-day oral formulation of a dual endothelia receptor antagonist (ERA). On October 1, the Institut national d’excellence en santé et services sociaux (INESSS) recommended that the Régie de l’assurance maladie du Québec (RAMQ) add Opsumit to the list of medications covered by the prescription drug insurance plan. This local development comes nearly a year after the drug’s Health Canada approval in November 2013 as a long-term treatment for PAH.
  •   
  • October 13, 2014
  • New Insights Into Monocrotaline Induced Pulmonary Hypertension
  • (Lung Disease News) A new study recently identified hexokinase-1 (HK1) as a potential target for therapeutic intervention for Pulmonary arterial hypertension (PAH). Entitled “Up-regulation of hexokinase1 in the right ventricle of monocrotaline induced pulmonary hypertension”, the study was published in the Respiratory Research journal by Dr. Wei-hua Zhang, part of the group of Dr. Yang Zheng, from the First Hospital of Jilin University, Changchun, China, and co-senior author Dr. Zhi-cheng Jing, and colleagues.
  •   
  • What Doctors Can Tell About Your Health Just By Looking At Your Feet
  • (Business Insider) The feet do a lot more than simply carry us from place to place. They can also provide important clues about our health, from showing us if we're dehydrated to pointing to bigger problems, like impaired circulation or lung disease.
  •   
  • 5 Victorian diseases back to haunt us
  • (BT.com) Thankfully, science and medicine has moved on quite a lot since Queen Victoria was on the throne.
    But, with reports of an alarming rise in everything from rickets to gout, it appears certain diseases have not.
    While we might be loving all things retro at the moment, filling our homes with mid-century sofas and dressing in questionable fashions of the 80s, we look at one vintage trend we don’t want be following…
  •   
  • October 12, 2014
  • Xolair Asthma Drug Associated With Higher Rate Of Heart Attacks, Pulmonary Hypertension, Blood Clots Causing PEs And/Or DVTs, And Brain Blood Vessel Problems
  • (Drug Injury Watch) In late September 2014 we learned more about serious side effects that have been linked to Xolair since this injectible drug for certain patients with asthma or chronic hives was approved in 2003.  The drug companies responsible for Xolair are Genentech and Novartis Pharmaceuticals.
  •   
  • Is inflammation a potential therapeutic target in chronic thromboembolic pulmonary hypertension?
  • (European Respiratory Journal) Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but notoriously underdiagnosed complication of pulmonary embolism, which carries a poor prognosis if left untreated. CTEPH results from the obstruction of the pulmonary vascular bed by fibro-thrombotic material, which may completely occlude the lumen.
  •   
  • October 11, 2014
  • PAH Treatments Could Be Developed From New Insights Into a Molecule in the Glycolytic Pathway
  • (Pulmonary Hypertension News) A protein within the glycolytic metabolism pathway, which is key to providing energy for cell processes, is increased in induced animal models of pulmonary arterial hypertension. This finding, reported in the journal Respiratory Research in an article entitled, “Up-regulation of Hexokinase 1 in the Right Ventricle of Monocrotaline Induced Pulmonary Hypertension,” may suggest another intervention for treating pulmonary arterial hypertension.
  •   
  • Effects of different mesenchymal stromal cell sources and delivery routes in experimental emphysema
  • (7th Space) Intravenous administration of BM- and AD-MSCs reduced the number of M1 macrophages and pulmonary hypertension on echocardiography, while increasing vascular endothelial growth factor. Only BM-MSCs (IV?>?IT) increased the number of M2 macrophages.
  •   
  • October 10, 2014
  • Chronic Thromboembolic Pulmonary Hypertension Disease Progression Mechanisms Uncovered
  • (Pulmonary Hypertension News) New research is shedding light on the progression of CTEPH. A novel study on chronic thromboembolic pulmonary hypertension (CTEPH), entitled “Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients” published in the European Respiratory Journal  by Dr. Diana Zabini, part of Dr. Andrea Olschewski ’s research group from Ludwig Boltzmann Institute for Lung Vascular Research and Division of Pulmonology, Medical University of Graz, Graz, Austria, shows that IP-10 secretion is associated with poor pulmonary haemodynamics and physical capacity in CTEPH, patients and may be involved in the pathogenesis of pulmonary endarterectomy (PEA) tissue formation.
  •   
  • Pulmonary Hypertension Can Complicate Treatment in the ICU
  • (Pulmonary Hypertension News) When admitted to the intensive care unit (ICU), chances are high that the patient has an existing condition in addition to the affliction causing their admittance to the ICU. It is vital that these existing conditions be considered by clinicians when developing a course of treatment, as many times treatments can be negatively impacted by features of the existing condition. Patients with pulmonary arterial hypertension are of particular importance when making these decisions, as complications from treatment can lead to heart failure or death.
  •   
  • October 9, 2014
  • An Implanted Sensor Is Helping Heart Patients
  • (The Ledger) A sensor implanted in Beck's pulmonary artery generates data about arterial pressure levels, a key indicator of whether her heart failure is worsening, and transmits the information for the doctor's review.
  •   
  • October 8, 2014
  • Management of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illness
  • (7t Space) Pulmonary arterial hypertension (PAH) is commonly treated with pulmonary arteriolar vasodilator therapy. When a patient on PAH medication is admitted to intensive care, determining how to manage their medication during the critical illness is often complicated
  •   
  • Confused Drug Names
  • (Pharmacy Times) Letairis or Letaris?
    LETARIS is a formerly marketed Dutch brand name for letrozole, which is indicated for the treatment of local or metastatic breast cancer that is hormone receptor–positive or breast cancer with unknown receptor status in postmenopausal women. Letrozole is known by the brand name FEMARA in the United States. LETAIRIS (note the “I” after the “A”) is ambrisentan, a drug approved by the FDA for primary pulmonary hypertension.
  •   
  • October 7, 2014
  • The 2014-2015 Flu Season: Vaccine Recommendations
  • (MedScape) Vaccine options available in the United States. Again this season, trivalent and quadrivalent vaccines will both be available. All nasal spray vaccines this season will be quadrivalent. Inactivated flu vaccines, which are administered as intramuscular and intradermal injections, will be available in both trivalent and quadrivalent formulations. As a reminder, CDC has not expressed a preference between these different routes of vaccine administration for adults, nor has CDC expressed a preference between trivalent and quadrivalent vaccine. Don't delay vaccination if the quadrivalent vaccine is not available. Both types of vaccine offer important protection from flu.
  •   
  • October 5, 2014
  • Targeted treatments may improve idiopathic PAH survival
  • (Medwire) Patients with idiopathic pulmonary arterial hypertension (IPAH) may live longer if they are given targeted treatments than if they receive conventional management, researchers suggest.
  •   
  • Data for Promedior’s Idiopathic Pulmonary Fibrosis Drug PRM-151 Released
  • (Pulmonary Hypertension News) Promedior Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, has announced that retrospective quantitative imaging data from the company’s Phase 1b clinical trial of the drug PRM-151 for treatment of idiopathic pulmonary fibrosis (IPF), was presented in a poster at the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF) , held Sept 20-24 at Mont Tremblant, Quebec — a small resort town located about one hour north of Montreal in the francophone region of Canada. This meeting brings together leaders, scientists, clinicians, fellows, students and patient advocates in lung fibrosis from around the world.
  •   
  • October 4, 2014
  • Producing Pulmonary Drugs in Plant Cells May Allow for Cheaper Treatments
  • (Medscape) Encapsulating protein drugs in plant cells might be a new, more affordable way to deliver them, researchers say.

    In murine studies, angiotensin-converting enzyme 2 (ACE2) and its enzymatic product, angiotensin-(1-7) bioencapsulated in plant cells were effective against pulmonary hypertension.
  •   
  • Pulmonary Arterial Hypertension Patients With Congenital Heart Disease Experience Poor Quality of Life Scores
  • (Pulmonary Hypertension News) A team of scientists recently reported that patients with both pulmonary arterial hypertension and congenital heart disease (PAH-CHD) exhibit Quality of Life (QoL) scores significantly lower when compared to patients with stable PAH. The data were presented at the European Respiratory Society (ERS) Annual Congress.
  •   
  • October 3, 2014
  • The use of antidepressants and the risk of idiopathic pulmonary arterial hypertension
  • (Science Direct) Serotonin has been implicated in the development of idiopathic pulmonary arterial hypertension (IPAH). Drugs modulating serotonin pathways, including anti-depressants, have been associated with the incidence of IPAH, with conflicting reports as to the direction of the effect. We aimed to determine whether antidepressant exposure is associated with the incidence of IPAH.
    [..]
    The use of antidepressants was associated with a significantly increased risk of developing IPAH. However, the consistency of this risk across all antidepressants and absence of a dose-response relationship suggests a non-causal association.
  •   
  • Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients
  • (European Respiratory Journal) Chronic thromboembolic pulmonary hypertension (CTEPH) is associated with chronic inflammation but the pathological mechanisms are largely unknown. Our study aimed to simultaneously profile a broad range of cytokines in the supernatant of pulmonary endarterectomy (PEA) surgical material, as well as prospectively in patients with CTEPH to investigate whether circulating cytokines are associated with haemodynamic and physical characteristics of CTEPH patients.
    [..]
    This study is the first to show that IP-10 secretion is associated with poor pulmonary haemodynamics and physical capacity in CTEPH and might be involved in the pathological mechanism of PEA tissue formation.
  •   
  • APT Therapeutics’ Apyrase-Based Investigational Drug Minimizes Damage from Heart Attack without Increasing Hemorrhage
  • (Pipeline Rewiew) ST. LOUIS, MO, USA I October 2, 2014 I APT Therapeutics, Inc. is developing an investigational new drug, APT102, for heart attack and stroke patients. According to a recent study published in Science Translational Medicine, APT102 maintained optimal blood flow and reduced damage to the heart muscle by 80% in animal model studies of heart attack. Drugs commonly used to prevent blood clots for heart attack and stroke patients carry a risk of serious bleeding events. In contrast, APT102 attenuated bleeding in the study..
    [..]
    APT Therapeutics™ is developing optimized human apyrases as safe and effective therapy for acute myocardial infarction, stroke and pulmonary arterial hypertension.
  •   
  • October 2, 2014
  • Bayer closes acquisition of Consumer Care Business of Merck & Co. Inc
  • (twst.com) Leverkusen, October 1, 2014 - Bayer has completed the acquisition of the consumer care business of the U.S. pharmaceuticals group Merck & Co., Inc., Whitehouse Station, New Jersey. The transaction closed on October 1, 2014, following receipt of required antitrust approvals. "This acquisition is a milestone for Bayer and we intend to continue the expansion of our attractive over-the-counter business both through organic growth and bolt-on acquisitions," explained Bayer CEO Dr. Marijn Dekkers.
    [..]
    The strategic pharma collaboration between Bayer and Merck & Co., Inc. in the field of soluble guanylate cyclase (sGC) modulators also comes into effect simultaneously. Bayer plans to strengthen its development options in the cardiology business with the global co-development and co-commercialization agreement, which has already been approved by the relevant antitrust authorities. Merck & Co., Inc. will make payments of up to USD 2.1 billion to Bayer. These include an up-front payment of USD 1 billion, which is to be paid shortly after completion as well as revenue-based milestone payments of up to USD 1.1 billion for future combined sales of certain jointly developed substances, including the pulmonary hypertension treatment Adempas? (riociguat)...
  •   
  • October 1, 2014
  • Noninvasive diagnosis ‘reliable’ for pulmonary hypertension diagnosis
  • (News Medical) Doppler echocardiography has good accuracy relative to right heart catheterisation for detecting pulmonary hypertension, shows a large study.
    The study involved 1695 patients at a single cardiac care centre who underwent Doppler echocardiography no more than 5 days before or after right heart catheterisation. 
    Researcher Sebastian Greiner (University of Heidelberg, Germany) and team say that their study is considerably larger than most previous analyses of noninvasive systolic pulmonary artery pressure (sPAP) measurement.
    “Although recommended in many guidelines and used routinely, noninvasive quantification of sPAP has never been tested sufficiently in unselected large patient populations undergoing routine echocardiography examination”, they write in the Journal of the American Heart Association...
  •   
  • Correcting Cardiac Arrhythmias in PAH Patients Can Improve Mortality Risk
  • (Pulmonary Hypertension News) A new study, entitled “Frequency of Supraventricular Arrhythmias in Patients With Idiopathic Pulmonary Arterial Hypertension” published in the American Journal of Cardiology reports that Supraventricular arrhythmias (SVAs) are associated with a higher risk of death in patients suffering from pulmonary arterial hypertension, and restoration of normal heart beating (sinus rhythm) led to clinical recovery. The new findings could lead to improved treatment options for those with PAH who are experiencing cardiac arrhythmias.
  •   
  • September 30, 2014
  • Iloprost reverses established fibrosis in experimental right ventricular failure.
  • (ERS-Journal) Inhaled iloprost improves RV function and reverses established RV fibrosis partially by preventing collagen synthesis and by increasing collagen turnover.
  •   
  • Acute Hemodynamic Response of Infused Fasudil in Patients with Pulmonary Arterial Hypertension: A Randomized, Controlled, Crossover Study
  • (International Journal of Cardiology) Infused fasudil improved pulmonary hemodynamics in patients with PAH without significant toxicity.
  •   
  • September 29, 2014
  • Hydrogen (H2) als PAH-treatment?
  • (Molecular Biologiy Reports) Chinese scientists put a stick containing elementary magnesium (Mg) into drinking water and produced hydrogen. The hydrogenated water was able to lower the pap in ph mice, according to the publisher. H2 is the smalles molecule and acts as selective antioxidant. 
  •   
  • September 28, 2014
  • New Targets For Pulmonary Arterial Hypertension Treatments Identified By Researchers
  • (Pulmonary Hypertension News) A new study published in September’s issue of the American Journal of Respiratory and Critical Care Medicine, entitled, “The Sphingosine Kinase 1 / Sphingosine-1-Phosphate Pathway in Pulmonary Arterial Hypertension” reports the discovery of two novel therapeutic targets to treat pulmonary arterial hypertension.
  •   
  • Lungs Affected by Idiopathic Pulmonary Fibrosis May Benefit From Inflammation
  • (Pulmonary Hypertension News) Despite the widely held observation that inflammation leads to deadly scarring in idiopathic pulmonary fibrosis, according to a new study conducted at the National Jewish Health, some inflammation may help in the healing and repair process of the lung. Assistant professor of cell biology Elizabeth Redente, PhD, and her research team discovered that the pro-inflammatory cytokine TNF-α is able to speed recovery of damaged lungs, as well as accelerate the resolution of the disease, during their research on a mouse model.
  •   
  • Trial Data Supporting Safety and Efficacy of FibroGen FG-3019 Idiopathic Pulmonary Fibrosis Drug Presented At ICLAF Colloquium
  • (Pulmonary Hypertension News) FibroGen Inc. will present the full data set from a clinical study of patients with Idiopathic Pulmonary Fibrosis (IPF), treated for 48 weeks with the company’s investigational drug FG-3019, at the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF) in progress this week at Mont Tremblant, Quebec — a small resort town located about one hour north of Montreal in the francophone region of Canada, running from Sept 20-24. This meeting brings together leaders, scientists, clinicians, fellows, students and patient advocates in lung fibrosis from around the world.
  •   
  • September 27, 2014
  • Patient-derived stem cells shed light on pulmonary hypertension
  • (Vanderbilt Research News) Pulmonary arterial hypertension (PAH) – high blood pressure in the lungs – has been linked to both heritable and idiopathic (spontaneous) causes. The underlying vascular changes that cause PAH are unclear and previous attempts to study changes in patient tissues have been limited by end-stage disease effects.
  •   
  • Right Ventricular Geometry and Function in Pulmonary Hypertension: Non-Invasive Evaluation
  • (Diseases) Pulmonary hypertension (PH) is a rare disease, which still carries a poor prognosis. PH is characterized by a pressure overload on the right ventricle (RV), which develops hypertrophy, followed by a progressive failure. Accordingly, recent evidence showed that RV function has an important prognostic role in patients with PH. Echocardiography, cardiac magnetic resonance (CMR), computed tomography, and nuclear imaging allow a non-invasive evaluation of the RV size and function, but only the first two are routinely used in the clinical arena. Some conventional echocardiographic parameters, such as TAPSE (tricuspid anular plane systolic excursion), have demonstrated prognostic value in patients with PH. Moreover, there are some new advanced echo techniques, which can provide a more detailed assessment of RV function. Three-dimensional (3D) echocardiography allows measurement of RV volumes and ejection fraction, and two-dimensional (2D) speckle tracking (STE), allows assessment of RV myocardial mechanics. CMR provides accurate measurement of RV volumes, ejection fraction, and mass and allows the characterization of the RV wall composition by identifying the presence of fibrosis by late gadolinium enhancement. Although CMR seems to hold promise for both initial assessment and follow-up of patients with PH, its main role has been restricted to diagnostic work-up only.
  •   
  • Researchers Uncover New Insights Into Vascular Receptor Autoantibodies in PAH Associated with SSc
  • (Pulmonary Hypertension News) A new study, entitled “Vascular Receptor Autoantibodies in Pulmonary Arterial Hypertension Associated with Systemic Sclerosis,” conducted at Charité University Hospital, Rheumatology and Clinical Immunology in Berlin, Germany, and published in the American Journal of Respiratory and Critical Care Medicine by first author on the study Dr. Mike O. Becker from the group of Dr. Gabriela Riemekasten, reveals that antibodies against endothelin receptor type A (ETAR) and angiotensin receptor type-1 (AT1R) are involved in Systemic sclerosis (SSc)-associated pulmonary arterial hypertension (PAH) pathogenesis.
  •   
  • September 26, 2014
  • Sarcoidosis-Associated Pulmonary Hypertension Highlighted By Recent Study
  • (Pulmonary Hypertension News) While a major population of pulmonary hypertension patients are diagnosed with idiopathic or arterial pulmonary hypertension, a population of patients with pulmonary hypertension patients due to sarcoidosis is no less affected by the condition. Estimates from a paper published in Seminars in Respiratory and Critical Care Medicine state that approximately 6-20% of sarcoidosis patients will develop pulmonary hypertension and see an increased risk of mortality.
  •   
  • Ontarians Celebrate Overdue Provincial Access to Only IPF Treatment
  • (Pulmonary Hypertension News) Patients diagnosed with IPF along with their significant others recently received the good news that they are finally getting access to the first approved treatment for their condition. The announcement came after 2 years of hopeful, indignant lobbying.
  •   
  • September 25, 2014
  • Surgery corrects pulmonary problem
  • (WDTN) For Carl Simmons of Washington Township, something as simple as walking was taxing, leaving him short of breath. That went on for two years before he had a life saving, innovative surgery.
  •   

News Archives
Take the Current Poll
View Current Poll Results To Date
View the Poll Archives